News

Key socioeconomic data that will help you care for your most vulnerable populations.

FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.

A new report reveals how personalized medicine can make patients healthier while lowering costs.

Operational issues aside, outcomes-based contracts can offer a two-fold benefit for managed care executives.

What MCOs should know about insurers’ plans for the marketplace exchanges in 2018.

Here are the top three reasons for medication adherence failure and how to overcome them.

The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.

Healthcare executives are starting to realize that preventing cyberattacks is not just a task for their IT departments and third-party security vendors.

A new study led by The University of California researchers and published in JAMA reveals surprising findings.

Based on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.

FDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.

What are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.

Our policy analyst explains why he believes single payer Medicare-for-all is a pipe dream.

The conference raised important points about value-based contracts and the specialty pharmacy space.

A Willis Towers Watson survey finds that employers see enhancing the employee experience in healthcare as key to boosting health engagement.

Find out how the American College of Physicians says population health data can decrease opioid addiction and abuse.

By 2025, the United States could be facing a shortage ranging from 34,600 to 88,000 physicians in total. Find out how this could affect population health initiatives.

Scott Gottlieb, MD, was sworn in as the new FDA commissioner and ushers in a new era.

Soon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.

Here are four things MCOs should know about a new study focusing on young patients with diabetes.

A new Willis Towers Watson survey finds that U.S. employers have three key strategies to building cost-effective healthcare programs. 

Humana’s goal is to improve the health of the communities it serves 20% by the year 2020. Find out how it is reaching this goal.

The Medical College of Wisconsin’s multiple myeloma program is robust and growing.

As President Trump promises fight the opioid epidemic, here are 14 things experts want him to know.

Ready to pack your bags for a little R&R? Here are a few favorite spots recommended by industry leaders.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

FDA recently approved the first new treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, in more than 20 years.

Walmart, CVS Health, and a number of other healthcare organizations are supporting a new multi-million dollar consumer campaign to combat high prescription drug prices.